TECLens
Overview
TECLens is a clinical-stage ophthalmic medical device company based in Stamford, Connecticut, focused on developing non-invasive vision correction technologies. Founded in 2013 by David E. Acker and Patrick Lopath, the company has become known for its innovative approach using Quantitative Corneal Cross-Linking (qCXL) technology. As of February 2025, TECLens has raised a total of $19.9 million in funding from sources like Johnson & Johnson Innovation and Yonjin Capital, affirming its position as a leader in non-incisional refractive technologies.
Recent Developments
- February 2025: TECLens secured $9.3 million in a Series A funding round co-led by Johnson & Johnson Innovation – JJDC Inc. and Yonjin Capital. The funds are intended to support the clinical development of TECLens' non-incisional refractive correction procedure, which utilizes corneal cross-linking (CXL) technology.
- July 2024: Johnson & Johnson announced they would be co-leading a forthcoming Series A round for TECLens, highlighting increasing interest and investment in the company's innovative vision correction solutions.
- Clinical Trials: TECLens has been advancing clinical studies, particularly focusing on presbyopia correction, leveraging their qCXL™ technology. This innovative approach aims to set new standards for precision and accessibility in refractive treatments.
- Technology Advances: The company's proprietary CXLens® device employs real-time monitoring with ultrasound, delivering a customized UV light pattern to reshape the cornea non-invasively. This advancement has seen initial success in treating conditions like keratoconus and holds future potential for broader applications in treating low-order myopia, hyperopia, and astigmatism.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2013 |
| Headquarters | Stamford, Connecticut, United States |
| Founders | David E. Acker, Patrick Lopath |
| Revenue | Not disclosed |
| Profits | Not disclosed |
| Key Investors | Johnson & Johnson Innovation, Yonjin Capital |
| Industry | Ophthalmic Medical Devices |
| Number of Employees | Not disclosed |
Early History
TECLens was founded in 2013 with a mission to revolutionize the field of ophthalmic treatments through the development of non-invasive technologies. Initially, the company focused on utilizing corneal cross-linking (CXL) as a more accessible and patient-friendly alternative to traditional refractive surgeries. Early backing by prominent investors like Johnson & Johnson Innovation suggested confidence in the company's unique approach and innovative technologies. TECLens’ development of the CXLens® device marked a significant milestone, helping to establish early clinical feasibility and interest in its potential application for various eye conditions.
Company Profile and Achievements
TECLens operates as a developer of advanced non-invasive vision correction solutions. Their flagship technology, Quantitative Corneal Cross-Linking (qCXL), stands out for using computational models to deliver precise ultraviolet (UV) light patterns tailored for each patient's eye. This approach facilitates the reshaping of the cornea without incisions, offering a safer and more comfortable alternative to traditional methods.
- 2017: TECLens launched initial studies on the application of its technology.
- 2019: Raised $200k in seed funding to further refine their qCXL technology.
- 2024: Partnered with health organizations to expand the scope of their research and to leverage insights into presbyopia and myopia treatments.
- 2025: Continued to grow market presence with the latest Series A funding round.
Current Operations and Market Position
TECLens holds a pioneering position in the ophthalmic device industry, offering technologies that redefine accessible vision correction. They lead advancements in non-incisional procedures that cater to patients who seek alternatives to laser or invasive surgeries. Their current market focus is on the extensive potential applications of qCXL across different refractive and therapeutic needs, establishing partnerships with leading health entities and steadily expanding their clinical trial prospects.
Conclusion
TECLens is carving out a niche in the ophthalmology sector with its pioneering non-invasive techniques for correcting vision disorders. The company’s commitment to advancing technologies that promise ease of access and enhanced patient comfort is reflected in their innovative CXLens® device. Looking forward, TECLens is expected to continue leading advancements in ophthalmic medical devices, potentially broadening its clinical applications and further solidifying its impact on the industry.